$ORXOY News

Last published 3y ago

3y agoORXOYNotice of Extraordinary General Meeting in Orexo AB (publ)PR NewswireUPPSALA, Sweden, Oct. 3, 2023 /PRNewswire/ -- Orexo AB (publ), Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at
3y agoORXOYOrexo Q2 2023 Interim ReportPR NewswireUPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights› Total net revenues of SEK 157.7 m (147.8)› EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal
3y agoORXOYOrexo Interim Report Q1 2023PR NewswireUPPSALA, Sweden, April 27, 2023 /PRNewswire/ -- Focusing operations on Orexo´s strengths Q1 2023 highlights Total net revenues of SEK 158.8 m (159.4) EBITDA of SEK -41.1 m (2.8), EBITDA excluding
3y agoORXOYReport from Orexo AB's annual general meetingPR NewswireUPPSALA, Sweden, April 18, 2023 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 18 April 2023 resolved, in accordance with the nomination committee's
3y agoORXOYOrexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124PR NewswireUPPSALA, Sweden, April 3, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, is delayed to late 2024 from
3y agoORXOYOrexo publishes the Annual and Sustainability Report for 2022PR NewswireUPPSALA, Sweden , March 28, 2023 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish in accordance with
3y agoORXOYOrexo postpones publication of the Annual ReportPR NewswireUPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for
3y agoORXOYNotice of Annual General Meeting of OrexoPR NewswireUPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at
3y agoORXOF ORXOYOrexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdosePR NewswireOX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioidsIf approved, the US launch is expected to be
3y agoORXOF ORXOYOrexo Interim Report Q4 2022, incl. Full Year ReportPR NewswireUPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5), EBITDA
3y agoORXOF ORXOYOrexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companiesPR NewswireOrexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stabilityOrexo has initiated two exploratory feasibility studies applying
3y agoORXOYOrexo to Webcast Live at VirtualInvestorConferences.com December 15thGlobeNewswireMORRISTOWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Orexo (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use
4y agoORXOF ORXOYOrexo Interim Report Q3 2022PR NewswireUPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal
4y agoORXOYOrexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUDPR NewswireStudy evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD)The study enrolled 437
4y agoORXOF ORXOYOrexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUDPR NewswireStudy evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD)The study enrolled 437
4y agoORXOF ORXOYOrexo appoints Edward Kim, M.D., as new Chief Medical OfficerPR NewswireUPPSALA, Sweden, Oct. 26, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael Sumner, M.D., who has held
4y agoORXOF ORXOYOrexo's Nomination Committee for the Annual General Meeting 2023PR NewswireUPPSALA, Sweden, Oct. 17, 2022 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same members as ahead of the AGM
4y agoORXOF ORXOYOrexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactionsPR NewswireAll four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine Data available today indicates significantly improved stability compared to
4y agoORXOF ORXOYOrexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patientsPR NewswireUPPSALA, Sweden, Sept. 7, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics.
4y agoORXOF ORXOYFirst patent issued in Europe for Orexo's adrenaline product OX640PR NewswireUPPSALA, Sweden, Sept. 1, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medicat
4y agoORXOYOrexo to participate in Pareto Securities' 13th Annual Healthcare ConferencePR NewswireSTOCKHOLM, Aug. 31, 2022 /PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and evidence-based digital therapeutics primarily targeting the US market where its commercial organization is located, today ann
4y agoORXOF ORXOYOrexo Interim Report Q2 2022PR NewswireUPPSALA, Sweden, July 14, 2022 /PRNewswire/ -- Good tailwind in the financial development Q2 2022 highlights Total net revenues of SEK 147.8 m (142.8) EBITDA of SEK -32.5 m (-41.1) Net earnings of SEK -35.8 m (-73.7) US Pharma segmen
4y agoORXOF ORXOYOrexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply SchedulePR NewswireOrexo is granted a Veterans Affairs Federal Supply Schedule contract for deprexis® in the US and will be reimbursed and made available by the federal government for use within the Veterans Affairs Health System, Indian Health Service and Department of
4y agoORXOF ORXOYOrexo's nasal adrenaline rescue medication OX640 enters clinical developmentPR NewswireOX640 has the potential to provide important benefits to patients and healthcare systems ensuring the correct adrenaline dose is both reliably and conveniently available - for the emergency treatment of allergic reactions If approved, the product will
4y agoORXOF ORXOYOrexo Interim Report Q1 2022PR NewswireUPPSALA, Sweden, April 28, 2022 /PRNewswire/ -- Promising start to 2022 Q1 2022 highlights Total net revenues of SEK 159.4 m (132.3) EBITDA of SEK 2.8 m (-23.9) Net earnings of SEK -23.
4y agoORXOF ORXOYOrexo's partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosisPR NewswireUPPSALA, Sweden, April 27, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of systemic scleros
4y agoORXOF ORXOYReport from Orexo AB's annual general meetingPR NewswireUPPSALA, Sweden, April 21, 2022 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 21 April 2022 resolved, in accordance with the nomination committee's proposal, that the number of board
4y agoORXOF ORXOYOrexo publishes 2021 Annual ReportPR NewswireUPPSALA, Sweden, March 31, 2022 /PRNewswire/ -- Orexo's Annual Report for the 2021 has been published. The Annual Report can be downloaded on the company's website, www.orexo.com, and a PDF is attached to this press release. The Swedish version is also
4y agoORXOF ORXOYNotice of Annual General Meeting of OrexoPR NewswireUPPSALA, Sweden, March 21, 2022 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Thursday 21 April 2022, at 16.00 pm in Orexo's facilities at
4y agoORXOF ORXOYOrexo appoints Fredrik Järrsten as new CFOPR NewswireUPPSALA, Sweden, March 11, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new Chief Financial Officer (CFO) and a member of the management team, starting at latest in e
4y agoORXOF ORXOYOrexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug ListPR NewswireUPPSALA, Sweden, Feb. 24, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This
4y agoORXOF ORXOYOrexo Q4 2021, incl. Full Year ReportPR NewswireUPPSALA, Sweden, Jan. 27, 2022 /PRNewswire/ -- Ready to capitalize on a strong foundation Q4 2021 highlights Total net revenues of SEK 144.0 m (159.2) Net earnings of SEK -66.0 m (-49.6) EBITDA of SEK -48.5 m (1.0) US Pharma segment (ZUBSOL
4y agoORXOF ORXOYOrexo develops a nasal adrenaline medication based on the novel amorphOXTM platformPR NewswireUPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Ad
4y agoORXOF ORXOYOrexo provides information about its new proprietary drug delivery platform - amorphOXTMPR Newswire- amorphOXTM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products with various active ingredients and administration routes - The amorphOXTM platform provides for exce
4y agoORXOF ORXOYOrexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124PR NewswireUPPSALA, Sweden, Nov. 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully completed the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The study met its prim
5y agoORXOF ORXOYOrexo's Nomination Committee for the Annual General Meeting 2022PR NewswireUPPSALA, Sweden, Nov. 1, 2021 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percent of the number of votes in the company as of September 30, 2021. The No
5y agoORXOYDigital Therapeutic MODIA™ Designed to Improve Medication-Assisted Treatment Experience for Opioid Use DisorderPR NewswireMORRISTOWN, N.J., Oct. 18, 2021 /PRNewswire/ -- Today Orexo announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Treatment of Opioid Use Disorder: De
5y agoORXOF ORXOYMODIA™ paper published in the Journal of Medical Internet Research Mental HealthPR NewswireUPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Trea
5y agoABSSF ABXXF ADDYY AKCCF+44OTC Markets Group Announces Quarterly Index Performance and RebalancingPR NewswireNEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® in
5y agoORXOF ORXOYOrexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trialPR NewswireUPPSALA, Sweden, July 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The first cohort of hea
5y agoORXOF ORXOYSober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with OrexoPR NewswireMORRISTOWN, N.J., July 12, 2021 /PRNewswire/ -- Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober Grid's more than 300,000 users will gain access to Orexo
5y agoORXOF ORXOYOrexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®PR NewswireUPPSALA, Sweden, July 12, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) and Sober Grid, the largest social media network for those in addiction recovery, today announced that Sober Grid's more than 300,000 users will gain access to Ore
5y agoORXOF ORXOYOrexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUDPR NewswireUPPSALA, Sweden, July 1, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone,
5y agoORXOF ORXOYOrexo continues to strengthen ZUBSOLV's patent portfolio with two new patentsPR NewswireUPPSALA, Sweden, June 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents relating to ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone t
6y agoCLBS SLRX ORXOYVirtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020GlobeNewswireCompany executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today...